Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15615238 | 0.92 | BTK (0.43) | BTKPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL15615228 | 0.88 | PTGS1 (0.40) | BTKPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL15615093 | 0.84 | PTGS1 (0.33) | BTKPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL15615087 | 0.84 | BTK (0.39) | BTKPTGS1PTGS2 | |
| SCHEMBL16749767 | 0.83 | BTK (0.35) | BTKKDM4EALDH1A1 | |
| SCHEMBL15615221 | 0.82 | BTK (0.38) | BTKPTGS1PTGS2 | |
| SCHEMBL15614923 | 0.82 | BTK (0.42) | BTK | |
| SCHEMBL18900802 | 0.81 | KDM4E (0.34) | BTKKDM4EALDH1A1 | |
| SCHEMBL15615227 | 0.81 | BTK (0.39) | BTK | |
| SCHEMBL16749820 | 0.76 | BTK (0.38) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795608-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| EP-2870158-B1 | 1-[4-(3-PHENOXY)-PHENYL]-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7-YL-AMINE DERIVATIVES AS BRUTON'S TYROSINE KINASE (BTK) INHIBITORS FOR THE TREATMENT OF E.G. PROLIFERATIVE DISEASES | PHARMASCIENCE INC (CA) | 2017-05-31 | — | — | EP | disclosed |
| US-9447102-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2016-09-20 | — | — | US | disclosed |
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | GB005, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2014005217-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | TEC, BTK, LCK | BTK 2/4885PTGS1 1230/4885PTGS2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.